COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS IBRITUMOMAB TIUXETAN IN THE TREATMENT OF RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA IN CANADA

被引：0
|
作者：
Lachaine, J. [1 ]
Beauchemin, C. [1 ]
Mathurin, K. [1 ]
Aissa, F. [2 ]
机构：
[1] Univ Montreal, Montreal, PQ, Canada
[2] Lundbeck Canada Inc, Montreal, PQ, Canada
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A141 / A142
页数：2
相关论文
共 50 条
  • [41] THE COST-EFFECTIVENESS OF BENDAMUSTINE-RITUXIMAB (BEN-R) VERSUS R-CHOP FOR THE FIRST LINE TREATMENT OF PATIENTS WITH INDOLENT NON HODGKIN'S LYMPHOMA (INHL) IN COLOMBIA
    Wehler, E. A.
    Kowal, S.
    Ariza, J. G.
    Zambrano, C.
    de Anda, J. A.
    Anaya, P.
    Munakata, J.
    Gonzalez, L.
    VALUE IN HEALTH, 2015, 18 (07) : A818 - A819
  • [42] Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study
    Cheson, Bruce D.
    Trneny, Marek
    Bouabdallah, Kamal
    Dueck, Gregory
    Gribben, John
    Lugtenburg, Pieternella J.
    Press, Oliver
    Salles, Gilles A.
    Fingerle-Rowson, Gunter
    Mattiello, Federico
    Wassner-Fritsch, Elisabeth
    Sehn, Laurie H.
    BLOOD, 2016, 128 (22)
  • [43] Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma
    Marcus, R
    SEMINARS IN ONCOLOGY, 2005, 32 (01) : S36 - S43
  • [44] Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma
    Wiseman, GA
    Leigh, B
    Erwin, WD
    Lamonica, D
    Kornmehl, E
    Spies, SM
    Silverman, DHS
    Witzig, TE
    Sparks, RB
    White, CA
    CANCER, 2002, 94 (04) : 1349 - 1357
  • [45] Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
    Cheson, Bruce D.
    Chua, Neil
    Mayer, Jiri
    Dueck, Greg
    Trneny, Marek
    Bouabdallah, Kamal
    Fowler, Nathan
    Delwail, Vincent
    Press, Oliver
    Salles, Gilles
    Gribben, John G.
    Lennard, Anne
    Lugtenburg, Pieternella J.
    Fingerle-Rowson, Gunter
    Mattiello, Federico
    Knapp, Andrea
    Sehn, Laurie H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2259 - +
  • [46] BendamustineA Review of its Use in the Management of Chronic Lymphocytic Leukaemia, Rituximab-Refractory Indolent Non-Hodgkin’s Lymphoma and Multiple Myeloma
    Sheridan M. Hoy
    Drugs, 2012, 72 : 1929 - 1950
  • [47] Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma
    Fowler, N. H.
    McLaughlin, P.
    Kwak, L.
    Hagemeister, F.
    Fanale, M.
    Fayad, L.
    Pro, B.
    Samaniego, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Cost Effectiveness of Rituximab for Non-Hodgkin's Lymphoma A Systematic Review
    Auweiler, Philipp W. P.
    Mueller, Dirk
    Stock, Stephanie
    Gerber, Andreas
    PHARMACOECONOMICS, 2012, 30 (07) : 537 - 549
  • [49] Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
    Tang, Xiao
    Chen, Xudong
    Zhang, Tiantian
    Jiang, Jie
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [50] Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
    Gordon, LI
    Witzig, TE
    Wiseman, GA
    Flinn, IW
    Spies, SS
    Silverman, DH
    Emmanuolides, C
    Cripe, L
    Saleh, M
    Czuczman, MS
    Olejnik, T
    White, CA
    Grillo-López, AJ
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 87 - 92
12345